Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Prosaposin in CNS health and disease, metabolic stress and exercise adaptation

doi: 10.1007/s00109-026-02643-3

Figure Lengend Snippet: Overview of prosaptide peptides derived from the saposin C domain of prosaposin (PSAP) and their tested therapeutic applications. The full saposin C sequence is shown at the top, with the neurotrophic region ( LIDNNKTEKEIL ) highlighted in green and underlined. Left panel: Sequences of various bioengineered or truncated prosaptide peptides tested in previous studies. Conservative amino acid substitutions (*) and lysine deletions (-) are indicated. Bioactivity is noted where tested. Right panel: Mapping of each prosaptide or full saposin (A–D) to specific disease-relevant therapeutic conditions, including oxidative stress, trauma/injury, ischemia, synucleinopathies, diabetes, allodynia, drug-induced toxicity, and Alzheimer’s disease-related Aβ/tau pathology. Checkboxes indicate whether the peptide has been evaluated in vitro, in vivo, or both. Peptides derived from the neurotrophic region, such as TX14(A), 769, and PS18, show diverse functional relevance across multiple disease models. Created with BioRender.com

Article Snippet: 39269584 , Taha et al. , 2024 , USA , In vivo: C57/B6L male young (3 months) mice , None , PS18 , In vivo: subcutaneous injection daily for 7 days , 2.0 mg/kg PS18 , PS18 obtained from Phoenix Pharmaceuticals (324–431) , PS18-injected animals showed modest but unpowered and independently unvalidated increases in BDNF, SNAP25, and PSD95 in cortical synapatosome fractions. Additionally, there were nonsignificant trends towards increases for SYP1, SYT1, and SAP97 in the cortical synaptosome fractions.

Techniques: Derivative Assay, Sequencing, In Vitro, In Vivo, Functional Assay